How the trans Pacific partnership agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand

Health Policy

Volumn 112, Issue 3, 2013, Pages 227-233

  Gleeson, Deborah ^a   Lopert, Ruth ^b   Reid, Papaarangi ^c  

^a LA TROBE UNIVERSITY   (Australia)

^b THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^c THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Access to medicines; Health equity; Pharmaceutical coverage programs; Trade agreements

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUSTRY; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRESCRIPTION; REIMBURSEMENT;

ACCESS TO MEDICINES; HEALTH EQUITY; PHARMACEUTICAL COVERAGE PROGRAMS; TRADE AGREEMENTS;

COMMERCE; COST CONTROL; DECISION MAKING; DRUG AND NARCOTIC CONTROL; DRUG COSTS; ECONOMIC COMPETITION; HEALTH EXPENDITURES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNATIONAL COOPERATION; NEGOTIATING; NEW ZEALAND; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 84887047934     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.07.021     Document Type: Article

References (35)

1. Ragupathy R., Aaltonen K., Tordoff J., Norris P., Reith D. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. PharmacoEconomics 2012, 30(11):1051-1065.
2. Cummings J., Mays N. How New Zealand has contained expenditure on drugs. BMJ 2010, 340:1224-1227.
3. Braae R., et al. Managing pharmaceutical expenditure while increasing access: the PHARMAC experience. PharmacoEconomics 1999, 16(6):649-660.
4. New Zealand Government. Press Release Hon Tony Ryall Minister of Health: Smarter Purchasing to Deliver Savings to Health. 07.09.12. Available at: http://www.scoop.co.nz/stories/PA1209/S00089/smarter-purchasing-to-deliver-savings-to-health.htm.
5. Pharmaceutical Management Agency (PHARMAC) Introduction to PHARMAC: Information Sheet; 2012. Available at: http://www.pharmac.govt.nz/2011/09/16/01INTRO.pdf.
6. Spinks J.M., Richardson J.R.J. Paying the right price for pharmaceuticals: a case study of why the comparator matters. Australian Health Review 2011, 35:267-272.
7. PHARMAC Purchasing Medicines: Information Sheet. 2013. Available at: http://www.pharmac.health.nz/ckeditor_assets/attachments/378/infosheet-05-purchasing-medicines-2013.pdf.
8. OECD OECD Health Data 2011, Organisation for Economic Co-operation and Development, Paris.
9. Aaltonen K., Ragupathy R., Tordoff J., Reith D., Norris P. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand. Value in Health 2010, 13(1):148-156.
10. PHARMAC. Pharmaceutical Management Agency Annual Report for the Year Ended 30 June 2012. Available at: http://www.pharmac.govt.nz/2012/11/07/2011.12%20Annual%20Report.pdf.
11. Ministry of Health, New Zealand Government. Prescription Charges; 2013. Available at: http://www.health.govt.nz/your-health/conditions-and-treatments/treatments-and-surgery/medications/prescription-charges.
12. Australian Government Department of Health and Ageing. About the PBS. 2013. http://www.pbs.gov.au/info/about-the-pbs%23What_are_the_current_patient_fees_and_charges.
13. United States Trade Representative. 2012 Special 301 Report. USTR, Executive Office of the President of the United States: Washington D.C.; 2012. Available at: http://www.ustr.gov/sites/default/files/2012%20Special%20301%20Report.pdf.
14. Lopert R., Gleeson D. The high price of free trade: US trade agreements and access to medicines. Journal of Law, Medicine and Ethics 2013, 41(1):199-223.
15. Gleeson D. Analysis of the June 2011 Leaked TPP Transparency Chapter Annex. Submission to the Department of Foreign Affairs and Trade. 2012, Available at: http://www.dfat.gov.au/fta/tpp/subs/tpp_sub_gleeson_120911.pdf.
16. Flynn S, Kaminski M, Baker BK, Koo JH. Public Interest Analysis of the US TPP Proposal for an IP Chapter. Draft Version 1.3. 2011. Available at: http://infojustice.org/wp-content/uploads/2011/12/TPP-Analysis-12062011.pdf.
17. Trans Pacific Partnership. Transparency Chapter - Annex on Transparency and Procedural Fairness for Healthcare Technologies. [Leaked draft text]. 22.06.11. Available at: http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificTransparency.pdf.
18. Inside US Trade US Tables TPP Drug Pricing Proposal; Still Mulling Other IPR Provisions. 14.09.12.
19. Park S.E., Lim S.H., Choi H.W., Lee S.M., Kim D.W., Yim E.Y., Kim K.H. Yi SY evaluation on the first 2 years of the positive list system in South Korea. Health Policy 2011, 104:32-39.
20. Morgan S.G., McMahon M., Mitton C., Roughead E., Kirk R., Kanavos P., Menon D. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Affairs 2006, 25(2):337-347.
21. Medicines New Zealand. Media Release Access to Medicine and the Trans-Pacific Partnership. 2012. http://www.medicinesnz.co.nz/media-releases/.
22. PHARMAC Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees. 2008, Pharmaceutical Management Agency, New Zealand Government, Wellington, Available at:. http://www.pharmac.govt.nz/2008/10/30/2008%20PTAC%20ToR.pdf.
23. Flood C.M. The evidentiary burden for overturning government's choice of regulatory instrument: the case of direct-to-consumer advertising of prescription drugs. University of Toronto Law Journal 2010, 60(2):397-424.
24. Frosch D.L., Grande D., Tarn D.M., Kravitz R.L. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Health Policy and Ethics 2010, 100(1):24-32.
25. Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Quality and Safety in Health Care 2005, 14:246-250.
26. Toop L., Richards D., Dowell T., Tilyard M., Fraser T., Arroll B. Direct to consumer advertising of prescription drugs in New Zealand: for health or for profit? Report to the Minister of Health supporting the case for a ban on DTCA 2003, University of Otago, Christchurch.
27. Trans Pacific Partnership Intellectual Property Rights Chapter: Draft - 10.02.11. [Leaked draft text]. Available at: http://keionline.org/sites/default/files/tpp-10feb2011-us-text-ipr-chapter.pdf.
28. Trans Pacific Partnership Intellectual Property Rights Chapter - Selected Provisions; September 2011. [Leaked draft text]. Available at: http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificIP1.pdf.
29. Public Citizen Dangers for Access to Medicines in New Zealand: Intellectual Property in the TPP. Washington D.C. Public Citizen's Global Access to Medicines Program; 2012. Available at: http://www.citizen.org/documents/NZ-TPP1-pagerfinal-1.pdf.
30. Trans Pacific Partnership. Investment Chapter [Leaked draft text]; 2012. Available at: http://www.citizenstrade.org/ctc/wp-content/uploads/2012/06/tppinvestment.pdf.
31. Jatrana S., Crampton P., Norris P. Ethnic differences in access to prescription medication because of cost in New Zealand. Journal of Epidemiology and Community Health 2011, 65:454-460.
32. Mills C., Reid P., Vaithianathan R. The cost of child health inequalities in Aotearoa New Zealand: a preliminary scoping study. BMC Public Health 2012, 12:384. 10.1186/1471-2458-12-384.
33. New Zealand Government (2000). New Zealand Public Health and Disability Act 2000. Available at: http://www.legislation.govt.nz/act/public/2000/0091/latest/DLM80051.html%3Fsrc=qs.
34. Levy, D. No Pharmac in Trans-Pacific Partnership. Stuff.co.nz. 16.11.11. Available at: http://www.stuff.co.nz/national/politics/5978921/No-Pharmac-in-Trans-Pacific-Partnership.
35. Inside US Trade. Groser NZ seeking reasonable compromises on PHARMAC, GIs. Posted 3.12.12.